These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 30676789)

  • 21. Responses of state Medicaid programs to buprenorphine diversion: doing more harm than good?
    Clark RE; Baxter JD
    JAMA Intern Med; 2013 Sep; 173(17):1571-2. PubMed ID: 23877740
    [No Abstract]   [Full Text] [Related]  

  • 22. Decline in Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail.
    Soper R; Appajosyula S; Deximo C
    Adv Ther; 2018 Apr; 35(4):457-466. PubMed ID: 29623562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors associated with Medicaid patients' access to buprenorphine treatment.
    Baxter JD; Clark RE; Samnaliev M; Leung GY; Hashemi L
    J Subst Abuse Treat; 2011 Jul; 41(1):88-96. PubMed ID: 21459544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medication Treatment For Opioid Use Disorders In Substance Use Treatment Facilities.
    Mojtabai R; Mauro C; Wall MM; Barry CL; Olfson M
    Health Aff (Millwood); 2019 Jan; 38(1):14-23. PubMed ID: 30615514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medicaid coverage of medications to treat alcohol and opioid dependence.
    Mark TL; Lubran R; McCance-Katz EF; Chalk M; Richardson J
    J Subst Abuse Treat; 2015 Aug; 55():1-5. PubMed ID: 25921475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees.
    Stein BD; Dick AW; Sorbero M; Gordon AJ; Burns RM; Leslie DL; Pacula RL
    Subst Abus; 2018; 39(4):419-425. PubMed ID: 29932847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Barriers Rural Physicians Face Prescribing Buprenorphine for Opioid Use Disorder.
    Andrilla CHA; Coulthard C; Larson EH
    Ann Fam Med; 2017 Jul; 15(4):359-362. PubMed ID: 28694273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medicaid Expansion and Availability of Opioid Medications in the Specialty Substance Use Disorder Treatment System.
    Abraham AJ; Yarbrough CR; Harris SJ; Adams GB; Andrews CM
    Psychiatr Serv; 2021 Feb; 72(2):148-155. PubMed ID: 33267651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physicians as Mediators of Health Policy: Acceptance of Medicaid in the Context of Buprenorphine Treatment.
    Knudsen HK; Studts JL
    J Behav Health Serv Res; 2019 Jan; 46(1):151-163. PubMed ID: 30069622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.
    Jones CM; McCance-Katz EF
    Addiction; 2019 Mar; 114(3):471-482. PubMed ID: 30194876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proliferation of Cash-Only Buprenorphine Treatment Clinics: A Threat to the Nation's Response to the Opioid Crisis.
    Van Zee A; Fiellin DA
    Am J Public Health; 2019 Mar; 109(3):393-394. PubMed ID: 30726142
    [No Abstract]   [Full Text] [Related]  

  • 32. A comparison of adherence, outcomes, and costs among opioid use disorder Medicaid patients treated with buprenorphine and methadone: A view from the payer perspective.
    Kinsky S; Houck PR; Mayes K; Loveland D; Daley D; Schuster JM
    J Subst Abuse Treat; 2019 Sep; 104():15-21. PubMed ID: 31370980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine.
    Clark RE; Samnaliev M; Baxter JD; Leung GY
    Health Aff (Millwood); 2011 Aug; 30(8):1425-33. PubMed ID: 21821560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age related medication for addiction treatment (MAT) use for opioid use disorder among Medicaid-insured patients in New York.
    Neighbors CJ; Choi S; Healy S; Yerneni R; Sun T; Shapoval L
    Subst Abuse Treat Prev Policy; 2019 Jun; 14(1):28. PubMed ID: 31238952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.
    Samples H; Williams AR; Olfson M; Crystal S
    J Subst Abuse Treat; 2018 Dec; 95():9-17. PubMed ID: 30352671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medicaid participation among practitioners authorized to prescribe buprenorphine.
    Saunders H; Britton E; Cunningham P; Saxe Walker L; Harrell A; Scialli A; Lowe J
    J Subst Abuse Treat; 2022 Feb; 133():108513. PubMed ID: 34148758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. States' implementation of the Affordable Care Act and the supply of physicians waivered to prescribe buprenorphine for opioid dependence.
    Knudsen HK; Lofwall MR; Havens JR; Walsh SL
    Drug Alcohol Depend; 2015 Dec; 157():36-43. PubMed ID: 26483356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urine drug testing among Medicaid enrollees initiating buprenorphine treatment for opioid use disorder within 9 MODRN states.
    Hammerslag L; Talbert J; Donohue JM; Sharbaugh M; Ahrens K; Allen L; Austin AE; Gordon AJ; Jarlenski M; Kim JY; Mohamoud S; Tang L; Burns M;
    Drug Alcohol Depend; 2023 Sep; 250():110875. PubMed ID: 37413960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Buprenorphine prescribing practice trends and attitudes among New York providers.
    Kermack A; Flannery M; Tofighi B; McNeely J; Lee JD
    J Subst Abuse Treat; 2017 Mar; 74():1-6. PubMed ID: 28132694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability.
    Koch AL; Arfken CL; Schuster CR
    Drug Alcohol Depend; 2006 Jul; 83(3):274-8. PubMed ID: 16413146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.